combating sepsis mortality

combating sepsis mortality

The causes of high mortality from sepsis have been elusive for decades. In mid-December, clinical and industrial specialists presented data showing that the majority of septic mortality can be prevented by three mortality pathways (90%). Professor Konrad Reinhart of the Founding President of the Global Sepsis Alliance stressed that sepsis is still a medical emergency that is underserved as it is not available for authorized causal treatments and diagnostic remedies during the “Mortality in Sepsis” scientific symposium in Berlin hosted by SphingoTec GmbH (Hennigsdorf), together with Adrenomed AG and 4TEEN4 Pharmaceuticals.

One in 3.7 million septic patients diagnosed per year dies every 3.5 seconds. Reinhart emphasized that the true burden for systems inflammations leading to organ failure and reported six million dead per year, while the ICD-9 sepsis coding was widely underestimated (i.e. the US 30%, Sweden 15%). In addition, it was also illustrated in the S&D symposium Mortality in Sepsis. He pointed to the decline in mortality rates among early adoption countries including Australia, the United States and the United Kingdom through interventions such as (pneumony) immunization, early warning ratings, and septic awareness campaigns supported by the World Health Organization since 2017. What hasn’t changed for decadents, however, is the absence from early biomarkers to assess risk-sensitive patients who, upon admission to emergency departments (EDs) and intensive care units (ICUs, need aggressive medical intervention from the beginning).

The Medicines4Future Initiative which was launched ten years ago in Berlin was initiated by Dr. Andreas Bergmann, founder of SphingoTec GmbH, Adrenomed AG and 4TEEN4 PharmaceuticalsGmbH. “Inside MedicinesFuture we are trying to systematically investigate the causative mechanisms of sepsis mortality,” he explained, “and we have identified such mortality mechanisms based on forwarding observation studies and subsequent confirmation studies. ” Ten years after the serial founder had sold the traditional procalcitonin sepsis marker (PCT) to Thermo Fisher Scientific for € 330 million, Bergmann and his co-founders sold three separate mortality pathways into the Medicines4Future Initiative for B.R.A.H.M.S AG. Three different mortality pathway systems.

Biomarkers for decision support in critical care

The cell necrosis dependent cardiovascular depression and renal dysfunction induced by the bloodstream release of intracellular enzyme dipeptidyl peptidase 3 (Dp3) are one of the causes of mortality reported in the Medicine4Future Initiative. The DPP3 cleaves two main regulators, angiotensin II, and enkephalin, which cause organ malfunction and death in 20 percent of ICU-admitted patients.

Prof. Alexander Mebazaa of the Paris-based Hôpital of Lariboisière just issued preclinical and clinical data on the application of anti-DPP3 antibody procizumab in heart failure mice, developed by 4TEEN4 Pharmaceuticals GmbH, and high level of DPP3 correlated with that of the DPP3-induction symptoms, for example, a significant reduction in the heart reduction fraction.

Kidney dysfunction is the second cause of sepsis death. Around 10% (about 700,000) of the ICU patients die of deteriorated kidney function, causing acute kidney damage (AKI). SphingoTec said in January it plans to start a pencil CE-IVD POC test.  According to a broad spectrum of observational and new evidence from Professor Peter Pickkers (Radboud University, Nijmegen, Netherlands), PenKid is a practice in the realtime biomarkers of the kidney function that seems to predict the AKI for up to 48 hours before it begins. Recent publications indicate that penKid can be used to track the kidney function as well as the efficacy of the treatment in patients with AKI with a single measurement at ICU / ED entry. The output of the new penKid biomarker is directly compared to the normal replacement glomerular filtration rate (GFR) test, serum creatinine.